Search results
Results From The WOW.Com Content Network
Kite Pharma said it would receive an upfront payment of $40 million from the joint venture, funded by Fosun Pharma as well as regulatory and commercial milestones totaling $35 million. [ 54 ] On August 28, 2017, Gilead Sciences announced that it would purchase Kite Pharma for US$11.9 billion in cash ($180.00 per share). [ 55 ]
Based in Santa Monica, Kite Pharma is a commercial-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products with a primary focus on engineered autologous T cell therapy (eACT) designed to restore the immune system's ability to recognize and eradicate tumors. [14]
This page was last edited on 16 February 2024, at 22:50 (UTC).; Text is available under the Creative Commons Attribution-ShareAlike 4.0 License; additional terms may apply.
Apr. 20—Kite Pharma's Urbana cell therapy manufacturing facility has received federal approval for commercial production of its treatment for blood cancer, the global biopharmaceutical company ...
In September 2021, they subleased a much smaller office space in Santa Monica at the Pen Factory (a former Paper Mate factory) from Kite Pharma, which had leased the space from Lincoln Property Company. [62]
Santa Monica, California: view: 0000912242 MARA: Marathon Digital Holdings, Inc. Information Technology IT Consulting & Other Services Fort Lauderdale, Florida: view: 0001507605 MATV: Mativ Holdings, Inc. Materials Specialty Chemicals Alpharetta, Georgia: view: 0001000623 MATW: Matthews International Corporation Industrials Diversified Support ...
Two River Group Holdings is a New York-based venture capital firm and merchant bank focused on the life science sector. It specializes in investments in life science, biotechnology, and in firms focused on developing preventive and therapeutic technologies for a broad spectrum of disease areas including oncology, cardiovascular disease, neurological disorders, and companion animal health care.
It was developed by California-based Kite Pharma. [13] Axicabtagene ciloleucel was awarded U.S. FDA breakthrough therapy designation in October 2017, for diffuse large B-cell lymphoma, transformed follicular lymphoma, and primary mediastinal B-cell lymphoma. [14] [15] It also received priority review and orphan drug designation. [9]